Safety and efficacy of cefoperazone plus sulbactam versus ceftazidime in the empiric treatment of febrile neutropenia

Journal of Pharmacy Technology

Volumn 14, Issue 2, 1998, Pages 63-69

  Chandrasekar, Pranatharthi H ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFOPERAZONE; CEFTAZIDIME; FLUCONAZOLE; NORFLOXACIN; SULBACTAM; SULPERAZON;

ADOLESCENT; ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; CANCER PATIENT; CHILL; DIARRHEA; DRUG EFFICACY; DRUG MIXTURE; DRUG SAFETY; FEMALE; FEVER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; STAPHYLOCOCCUS; STREPTOCOCCUS; SUPERINFECTION;

EID: 0031947901     PISSN: 87551225     EISSN: None     Source Type: Journal    
DOI: 10.1177/875512259801400208     Document Type: Article

References (28)

1. Winston DJ, Ho WG, Bruckner DA, Champlin RE. Beta-lactam antibiotic therapy in febrile granulocytopenic patients: a randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin and imipenem alone. Ann Intern Med 1991;115: 849-59.
2. Pizzo PA, Hathorn JW, Hiemenz J, Browne M, Commers J, Cotton D, et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 1986;315:552-8.
3. Rolston KV, Berkey P, Bodey GP, Anaissie EJ, Khardori NM, Joshi JH, et al. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Arch Intern Med 1992;152:283-91.
4. Piccart M, Klastersky J, Meunier F, Lagast H, Van Laethem Y, Weerts D. Single-drug versus combination empirical therapy for gram-negative bacillary infections in febrile cancer patients with and without granulocytopenia. Antimicrob Agents Chemother 1984;30:64-8.
5. Bodey GP, Miller P, Ho DH. In vitro assessment of sulbactam plus cefoperazone in the treatment of bacteria isolated from cancer patients. Diagn Microbiol Infect Dis 1989;12(suppl):209S-14S.
6. Bolivar R, Weaver SS, Bodey GP. Activity of β-lactamase inhibitors in combination with new β-lactam antibiotics against resistant gram-negative organisms. Diagn Microbiol Infect Dis 1984;2:255-60.
7. Chandrasekar PH, Sluchak JA. In-vitro susceptibility of cefoperazone-susceptible and -resistant gram-negative rods to cefoperazone plus sulbactam, other beta-lactams, aminoglycosides and quinolones. Infection 1991;19:49-53.
8. Jones RN, Wilson HW, Thornsberry C, Barry AL. In vitro antimicrobial activity of cefoperazone-sulbactam combinations against 554 clinical isolates including a review and beta-lactamase studies. Diagn Microbial Infect Dis 1985;3:489-99.
9. Chandrasekar PH, Sluchak JA, Kruse JA. Therapy with cefoperazone plus sulbactam against disseminated infection due to cefoperazone-resistant Pseudomonas aeruginosa and Escherichia coli in granulocytopenic mice. Antimicrob Agents Chemother 1993;37: 1927-30.
10. Horiuchi A, Hasegawa H, Kageyama T, Yonezawa T, Kitani T, Masaoka T, et al. Efficacy of sulbactam/cefoperazone for the treatment of infections in patients with hematologic diseases. Diagn Microbiol Infect Dis 1989;12(suppl):215S-219S.
11. Bodey GP, Abi-Said D, Rolston K, Raad I, Whimbey E. Imipenem or cefoperazone-sulbactam combined with vancomycin for therapy of presumed or proven infection in neutropenic cancer patients. Eur J Clin Microbiol Infect Dis 1996;15:625-34.
12. Bodey GP, Elting LS, Narro J, Koller C, O'Brien S, Estey E, et al. An open trial of cefoperazone plus sulbactam for the treatment of fever in cancer patients. J Antimicrob Chemother 1993;32:141-52.
13. Hiemenz J, Favis G, Hiemenz S, Doughney K, Durkin W, Smith A, et al. Ceftazidime versus cefoperazone/sulbactam as initial empirical therapy for febrile neutropenic cancer patients (abstract). Presented at the Seventh International Symposium on Infections in the Immunocompromised Host, Boulder, CO, June 21-24, 1992.
14. Bickers JC, Gumbart C, Vial R, Veith R, McCormick C, Fussell S, et al. A prospective randomized trial of cefoperazone + sulbactam versus imipenem-cilastatin in febrile neutropenic patients (abstract). Presented at the 18th International Congress on Chemotherapy, International Society of Chemotherapy, Stockholm, Sweden, June 1993.
15. Winston DJ, Bartoni K, Schiller GJ, Bruckner DA. Cefoperazone-sulbactam versus imipenem for empiric monotherapy of febrile granulocytopenia (abstract). Presented at the 18th International Congress on Chemotherapy, International Society of Chemotherapy, Stockholm, Sweden, June 1993.
16. Sanders CC, Sanders WE. Beta-lactam resistance in gram-negative bacteria: global trends and clinical impact. Clin Infect Dis 1992;15:824-39.
17. Wade JC, Schimpff SC, Newman KA, Wiernik PH. Staphylococcus epidermidis: an increasing cause of infection in patients with granulocytopenia. Ann Intern Med 1992;97:503-8.
18. Viscoli C, Van der Auwera P, Meunier F. Gram-positive infections in granulocytopenic patients: an important issue? J Antimicrob Chemother 1988;21(suppl C):149-56.
19. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Reduction of fever and streptococcal bacteremia in granulocytopenic patients with cancer. JAMA 1994;272:1183-9.
20. Classen DC, Burke JP, Ford CD, Evershed S, Aloia MR, Wilfahrt JK, et al. Streptococcal sepsis in bone marrow transplant patients receiving oral antimicrobial prophylaxis. Am J Med 1990;89:441-6.
21. Kern W, Kurrle E, Schmeisser T. Streptococcal bacteremia in patients with acute leukemia undergoing aggressive cytotoxic chemotherapy. Infection 1990;18:138-45.
22. Guiot HFL, Peters WG, van der Broek PJ, van der Meer JA, Kramps JA, Willemze R, et al. Respiratory failure elicited by streptococcal septicemia in patients treated with cytosine arabinoside and its protection by penicillin. Infection 1990;18:131-7.
23. Bow R, Raynor R, Louie T. Comparison of norfloxacin with cotrimoxazole for infection prophylaxis in acute leukemia: the trade-off for reduced gram-negative sepsis. Am J Med 1988;84:847-54.
24. Gonzalez-Barca E, Fernandez-Sevilla A, Carratala J, Granena A, Gudiol F. Prospective study of 288 episodes of bacteremia in neutropenic cancer patients in a single institution. Eur J Clin Microbiol Infect Dis 1996;15:291-6.
25. Bow EJ, Loewen R, Vaughn D. Reduced requirement for antibiotic therapy targeting gram-negative organisms in febrile neutropenic patients with cancer who are receiving antimicrobial chemoprophylaxis with oral fluoroquinolones. Clin Infect Dis 1995; 20:907-12.
26. Boyce JM. Vancomycin-resistant Enterococcus: detection, epidemiology and control measures. Infect Dis Clin North Am 1997;11: 367-84.
27. Centers for Disease Control and Prevention. Preventing the spread of vancomycin resistance. Infect Control Hosp Epidemiol 1995:105-13.
28. Rubin M, Walsh TJ, Pizzo PA. Clinical approach to infections in the compromised host. In: Hoffman R, Benz EJ Jr, Shattil SJ, Furie B, Cohen HJ, eds. Hematology: basic principle and practice. New York: Churchill Livingstone, 1991:1063-114.